公开(公告)号：US12122821B2

公开(公告)日：2024-10-22

申请号：US16510220

申请日：2019-07-12

Applicant: H. LUNDBECK A/S

Inventor： Brian Baker ,  Jeffrey T.L. Smith ,  John Latham

IPC: C07K16/18 ,  A61K39/00 ,  C07K16/26 ,  G01N33/50 ,  G01N33/66

CPC classification number: C07K16/18 ,  G01N33/5038 ,  G01N33/5088 ,  G01N33/66 ,  A61K2039/505 ,  C07K16/26 ,  C07K2317/76 ,  G01N2333/5753

Abstract: The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance.

公开(公告)号：US11325967B2

公开(公告)日：2022-05-10

申请号：US16388184

申请日：2019-04-18

Applicant: H. LUNDBECK A/S ,  THE UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： Andrew F. Russo ,  Eric A. Kaiser ,  Ana Recober ,  Adisa Kuburas ,  Ann C. Raddant ,  Brian R. Kovacevich ,  John Latham ,  Jeffrey T. L. Smith ,  Leon F. Garcia-Martinez

IPC: C07K16/18 ,  A61K39/00

Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.
The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine. Specifically, this invention relates to assays and therapies using the antibodies described herein to inhibit or prevent photophobia, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them.

公开(公告)号：US20220073606A1

公开(公告)日：2022-03-10

申请号：US17397121

申请日：2021-08-09

Applicant: H. LUNDBECK A/S

Inventor： Andrew Lawrence Feldhaus ,  Leon F. Garcia-Martinez ,  Benjamin H. Dutzar ,  Daniel S. Allison ,  Katie Olson Anderson ,  Ethan Wayne Ojala ,  Pei Fan ,  Charlie Karasek ,  Jenny A. Mulligan ,  Danielle Marie Mitchell ,  Patricia Dianne McNeill ,  Michelle L. Scalley-Kim ,  Erica Stewart ,  Jeffrey T.L. Smith ,  John Latham

IPC: C07K16/26 ,  A61K39/395 ,  A61K45/06 ,  C07K16/42

Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-ACTH antibodies and binding fragments thereof for the diagnosis, assessment, prevention and treatment of diseases and disorders associated with ACTH, such as CAH, FGD, Cushing's Disease, Cushing's Syndrome, Parkinson's disease, obesity, diabetes, sleep disorders, depression, anxiety disorders, cancer, muscle atrophy, hypertension, hyperinsulinemia, cognitive dysfunction, Alzheimer's disease, galactorrhea, stress related conditions, cardiac conditions, metabolic syndrome, hyperaldosteronism, Conn's syndrome and familial hyperaldosteronism.

公开(公告)号：US11427631B2

公开(公告)日：2022-08-30

申请号：US16779889

申请日：2020-02-03

Applicant: H. LUNDBECK A/S.

Inventor： Andrew Lawrence Feldhaus ,  Leon Garcia-Martinez ,  Benjamin H. Dutzar ,  Daniel S. Allison ,  Katie Olson Anderson ,  Ethan Wayne Ojala ,  Pei Fan ,  Charlie Karasek ,  Jenny Mulligan ,  Michelle Scalley-Kim ,  Erica Stewart ,  Jeffrey T. L. Smith ,  John Latham

IPC: C07K16/26 ,  A61K39/00

Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-ACTH antibodies and binding fragments thereof for the diagnosis, assessment, prevention and treatment of diseases and disorders associated with ACTH, such as Cushing's Disease, Cushing's Syndrome, Parkinson's disease, obesity, diabetes, sleep disorders depression, anxiety disorders, cancer, muscle atrophy, hypertension, hyperinsulinemia, cognitive dysfunction, Alzheimer's disease, galactorrhea, stress related conditions, cardiac conditions, metabolic syndrome, hyperaldosteronism, Conn's syndrome and familial hyperaldosteronism.